Format

Send to

Choose Destination
Ther Clin Risk Manag. 2010 Oct 5;6:431-41. doi: 10.2147/TCRM.S4207.

Role of tipranavir in treatment of patients with multidrug-resistant HIV.

Author information

1
University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.

Abstract

The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.

KEYWORDS:

HIV; multidrug resistance; tipranavir

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center